【美国北极星医用放射性同位素公司网站2026年1月6日报道】美国北极星医用放射性同位素公司(NorthStar Medical Radioisotopes)近日宣布,已成功实现锕-225商业规模生产。这是业内首次使用电子加速器技术实现该同位素的商业化供应,标志...【美国北极星医用放射性同位素公司网站2026年1月6日报道】美国北极星医用放射性同位素公司(NorthStar Medical Radioisotopes)近日宣布,已成功实现锕-225商业规模生产。这是业内首次使用电子加速器技术实现该同位素的商业化供应,标志着放射性药物关键原料保障能力取得重要突破。展开更多
The radioisotope actinium-225(^(225)Ac)has been successfully used for targeted alpha therapy in preclinical and clinical applications because of its excellent nuclear characteristics.Medium-and high-energy proton-spal...The radioisotope actinium-225(^(225)Ac)has been successfully used for targeted alpha therapy in preclinical and clinical applications because of its excellent nuclear characteristics.Medium-and high-energy proton-spallation reactions on thorium are the most important methods for producing^(225)Ac.This study examines the possibility of producing^(225)Ac by irradiating thorium oxide with medium-energy protons.Thorium-oxide sheets were irradiated with 40-,50-,60-,70-,and 80-Me V protons on the Associated Proton-beam Experiment Platform(APEP)of the China Spallation Neutron Source(CSNS).The cross sections for the formation of^(225)Ac were measured using the activation method and offline gamma-ray spectrometric technique.The experimental results were compared with the existing data from EXFOR as well as the theoretical data from the TALYS-based evaluated nuclear-data library.Based on the experimental cross section and theoretical calculations,the production yield of^(225)Ac in the irradiated thorium targets was examined.The results showed that APEP can produce sufficient quantities of^(225)Ac for purification and clinical therapy.This work is the first measurement of proton-induced nuclearreaction cross sections at the CSNS APEP.展开更多
文摘【美国北极星医用放射性同位素公司网站2026年1月6日报道】美国北极星医用放射性同位素公司(NorthStar Medical Radioisotopes)近日宣布,已成功实现锕-225商业规模生产。这是业内首次使用电子加速器技术实现该同位素的商业化供应,标志着放射性药物关键原料保障能力取得重要突破。
基金supported by the National Natural Science Foundation of China(No.12075135)the National Natural Science Foundation of China(No.12375127)。
文摘The radioisotope actinium-225(^(225)Ac)has been successfully used for targeted alpha therapy in preclinical and clinical applications because of its excellent nuclear characteristics.Medium-and high-energy proton-spallation reactions on thorium are the most important methods for producing^(225)Ac.This study examines the possibility of producing^(225)Ac by irradiating thorium oxide with medium-energy protons.Thorium-oxide sheets were irradiated with 40-,50-,60-,70-,and 80-Me V protons on the Associated Proton-beam Experiment Platform(APEP)of the China Spallation Neutron Source(CSNS).The cross sections for the formation of^(225)Ac were measured using the activation method and offline gamma-ray spectrometric technique.The experimental results were compared with the existing data from EXFOR as well as the theoretical data from the TALYS-based evaluated nuclear-data library.Based on the experimental cross section and theoretical calculations,the production yield of^(225)Ac in the irradiated thorium targets was examined.The results showed that APEP can produce sufficient quantities of^(225)Ac for purification and clinical therapy.This work is the first measurement of proton-induced nuclearreaction cross sections at the CSNS APEP.
